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differences among the patients that could be explained by individual 
radiosensitivity. 
Materials and Methods: The salivary gland ejection (excretion) 
fraction (sEF) was measured by Tc-99m pertechnetate scintigraphy for 
50 patients receiving IMRT for head and neck cancer. The scintigraphy 
was performed before RT and repeated 6 and 12 months after RT. 
Only the glands with Dmean values between 15 Gy and 45 Gy were 
included and the glands which were not functioning properly prior to 
RT were excluded. The relative ejection fraction rEF(t) = sEF(t) / 
sEF(0) was first compared for both parotid glands of the same patient 
at the same time of measurement. Next, the rEF values at 6 and 12 
months after RT were compared for the same gland. To enable the 
comparison of rEF values between glands receiving varying Dmean, the 
mean effect of the absorbed dose on the gland was eliminated. This 
was achieved by dividing the rEF value for the gland with the 
respective value of sigmoidal mean dose response curve for the whole 
group of patients (rEF0=rEF(t)*(1+(Dmean/D50)^k)). Fisher’s exact test 
was used in the analysis with two categories defined by median rEF0. 
Average errors in Dmean values for the glands due to patient positioning 
errors were corrected based on portal images. 
Results: The values for rEF0 ranged from 0 to 2.7. A significant 
association between rEF0 for left and right parotid glands was found 
(χ2=6.0, p<0.025). Some patients show systematically lower or higher 
rEF0 than the median for both parotid glands. This could be explained 
by three possible reasons, as the effect of positioning errors to Dmean 
was excluded: 1) the variations result from the measurement 
technique or 2) the patients react differently to the lemon juice 
stimulus given during the scintigraphy or 3) the post-RT sEF is affected 
by varying individual responses to radiation. The rEF0 values for the 
same gland at 6 and 12 months after RT gave a statistically significant 
relationship between the two variables (χ2=4.73, p≤0.05) (Table 1). 
The same patients had low or high values of rEF0 for both parotid 
glands at both times of measurement. As this behaviour is seen in both 
measurements, it can not be due to fluctuations caused by 
measurement technique. Also, we believe that by using relative values 
instead of single sEF values, we can at least partly overcome the 
problem of patients reacting differently to the stimulus, assuming that 
the factors, such as smoking, that may influence saliva production 
remain the same between the measurements. As a result of this 
indirect deduction, we conclude that the systematic variation in rEF0 
reflects individual differences in radiosensitivity. 
 
 
Conclusions: According to our interpretation the systematic variations 
seen in post-RT salivary gland scintigraphy measurements can be 
explained by individual differences in radiosensitivity. Quantitative 
extraction of individual radiosensitivity requires further studies.  
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Purpose/Objective: Ferrofluid particles being subjected to an 
electromagnetic field show remarkable heating effects related to 
losses during the magnetization process and Joule heating of the 
particles. The temperature enhancement which occurs in a magnetic 
ferrofluid system under the influence of an external high frequency 
magnetic field has found applications in breast tumor hyperthermia 
treatment therapy. The main objectives are the uniformity of the 
temperature distribution and the target value of temperature to be up 
to 42°C in the controlled region for magnetic hyperthermia 
treatment. This temperature control is hard to implement because of 
many tissue individual variations and other therapy conditions. 
Materials and Methods: For determination of the thermal field 
distribution in magnetic hyperthermia therapy, a coupled 
electromagnetic – thermal - fluid dynamics field computational model 
is developed. The electromagnetic field distribution inside the 
conductive tissue region depends on the time varying magnetic flux 
density. The heat sources are defined by the electric losses in tissue, 
acquired by the solution of the electromagnetic field problem. The 
computational model uses anatomically precise multilevel geometrical 
model of human breast with known electrical tissue properties, blood 
and liquor flow speeds in its vessels. Model contains information about 
real cancer structure sample acquired by surgical procedure. Cancer 
and normal electrical tissue properties are directly measured for this 
sample by precise measurement system. 
Results: Sample under treatment is in stage T2N2M1 with maximal 
size of 25 mm. Sample volume is 317 mm3. Ferrofluid solution is 
injected at cancer sample. Ferrofluid filled volume in sample is 24 
mm3. Thermal field distribution in cancer model is presented in Fig.1. 
Maximal temperature acquired is 42.3oC. Temperature maximum 
represents the position of ferrofluid volume. Results from this model 
are validated by infrared thermography measurements of the sample. 
Field values and distributions correspond well to these one acquired 
by the model. 
 Fig.1 Thermal field distribution in tumor model for time period of 
120s. 
 
Conclusions: The coupled electromagnetic-fluid dynamics-thermal 
field computational modeling is capable to predict the magnetic 
ferrofluid hyperthermia thermal effects on live tissue. The developed 
model can be used for therapy planning and also design and 
optimization of interaction between electromagnetic devices and 
biological structures.  
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Purpose/Objective: To study whether genetic single nucleotide 
polymorphisms (SNPs) are predictive of erectile dysfunction (ED) in 
prostate cancer patients treated with radiotherapy, we investigated 
the relationship between genotypes in SNP data and Expanded 
Prostate Cancer Index Composite (EPIC) scores. 
Materials and Methods: In our previous study, we examined SNPs 
obtained for 124 prostate cancer patients who received radiotherapy 
(RT) and, after identifying a statistically-managable number of SNPs 
using a novel system biology approach, we indentified a single SNP 
(rs2032809) that was statistically associated with post-RT adverse 
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genitourinary (GU) and/or gastrointestinal (GI) late toxicity with p = 
0.0043 after Bonferroni correction in a recessive SNP model. This SNP 
belongs to BBC3/PUMA that plays a critical role in DNA damage-
induced apoptosis. EPIC-validated quality-of-life questionnaires were 
surveyed for these patients with a maximum follow-up of 5 years. In 
this study, we further tested the relationship between rs2032809 and 
EPIC scores (sexual function [SF], sexual bother [SB], and sexual 
domain summary [SS]).  
Results: At baseline, the mean SF, SB, and SS scores were 44.63 (95% 
confidence level [CI]: 39.53 – 49.45), 63.52 (95% CI: 58.20 – 69.13), 
and 50.40 (95% CI: 45.43 – 55.03), respectively. At 5-year follow-up, 
the mean SF, SB, and SS scores decreased by 41%, 30%, and 40%, 
respectively. A Mann-Whitney U test was used to investigate 
relationship between rs2032809 and EPIC scores. Significant 
associations were found with third-year SB (p = 0.039) and SS (p = 
0.037) scores (Figure 1). In the third year, the mean SB scores for 
those who have and do not have the minor allele were 71.53 and 
44.49, and 50.33 and 31.47 for the mean SS score, respectively, 
suggesting a considerable protective effect of this SNP. An additional 
test between the SNP and a fifth-year SF score yielded a borderline 
significant estimate (p = 0.090) and the mean SF scores were 45.76 
and 23.85, respectively, for those who have and do not have the 
minor allele.  
 
 Figure 1. Comparison of mean EPIC scores (+standard error of the 
mean) for patients who have GG+GA and AA genotypes in rs2032809 
using Mann-Whitney U test. SF: sexual function; SB: sexual bother; SS: 
sexual domain summary. 
Conclusions: We further examined a single BBC3/PUMA gene SNP 
(rs2032809) that was identified as a candidate biomarker of GI/GU 
toxicity in prostate cancer patients with a hypothesis as to whether 
this SNP is also correlated with sexual dysfunction. We observed a 
statistically significant association between the SNP and the third or 
fifth-year ED of patients. This further strengthens the evidence that 
this apoptosis gene is an important determinant of late toxicity and is 
affected by rs2032809.  
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Purpose/Objective: The aim of this study is to compare the 
protective effect of melatonin and amifostine on radiation induced 
acute renal damage.  
Materials and Methods: Fifty female albino rats were divided into five 
groups (with ten rats each): control (Cont), radiotherapy alone (RT), 
radiotherapy + amifostine (RT+AMI), radiotherapy + melatonin 
(RT+MEL), radiotherapy + amifostine + melatonin (RT+AMI+MEL). All 
experiments were conducted adhering to the guidelines of the 
institutional animal ethics committee. RT group were treated with 
only 0.9% saline solution 30 min before irradiation. Intraperitoneal 
amifostine (200 mg/kg) was administered to the rats in the RT+AMI 
and RT+AMI+MEL groups 30min before irradiation. Intraperitoneal 
melatonin (100 mg/kg) was administered to the rats in the RT+MEL 
and RT+AMI+MEL groups 30 min before irradiation. RT, RT+AMI, 
RT+MEL and RT+AMI+MEL groups were irradiated individually with a 
single dose of 8 Gy on whole body, using a Co-60 treatment unit 
(Cirus,cis-BioInt., Gif-sur-Yvette,France). Dose rate was 1.15 Gy/min. 
At the end of the follow-up period (72 hours) sacrification was done in 
all groups. Paraffin embedded kidney tissue samples were analyzed 
and percentage of damaged glomeruli was determined by counting 
damaged glomeruli of kidney cortex as segmental or total necrosis for 
each animal. 
Results: The percentage of damaged glomeruli is presented in Table 
1. The protective effectof amifostine, melatonin, and amifostin plus 
melatonin on radiation induced renal toxicity is statistically 
meaningful (p 0.000, 0.003, 0.000, respectively). There is an 
advantage in favor of melatonin when compared with amifostine (p 
0.005). Although there is not an advantage of adding amifostine to 
melatonin when compared with melatonin alone (p 0.243), there is 
statistically significant better protective effect in amifostine plus 
melatonin group when compared with amifostine alone group (p 
0.003). As there was no significant damage following 8 Gy whole body 
irradiation on the kidney tubule, the protective effect of any agent 
could not be assessed. 
 
Table 1. The percentage of damaged glomeruli 
 Groups 
 ContRT RT+AMI RT+MELRT+AMI+MEL 
Glomeruli 
damage (%)
0 40 30 20 20 
0 40 40 20 30 
0 50 40 30 30 
0 40 30 25 30 
0 50 20 20 20 
0 40 30 20 15 
0 40 30 25 20 
0 50 40 30 15 
0 40 40 20 15 
0 40 30 30 20 
 
 
Conclusions: In this study, it has shown that the protective effect of 
melatonin on radiation induced acute renal toxicity is better than 
amifostine. These results are encouraging for the clinical use of 
melatonin. 
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Purpose/Objective: To investigate possible synergetic effects 
between dose to the anal-sphincter region and dose to the rectum for 
the occurrence of long-term fecal leakage after radiation therapy for 
prostate cancer. 
Materials and Methods: For the current analyses we included 414 
prostate-cancer survivors who had received external beam radiation 
therapy (EBRT) to a total dose of 70 Gy in 2 Gy daily fractions 
between 1993 and 2006. We also included 332 population-based 
controls matched for age and residency. EBRT was delivered using one 
anterior–posterior and two lateral wedged field. The planning target 
volume comprised the prostate or post-operative prostatic region with 
20 mm margin except for the rectal margin, which was 15 mm or 
maximum half the rectal cross-sectional area. We restored original 
